Momelotinib Improves Symptoms of Myelofibrosis
The proportion of patients with a 50% or greater reduction in total symptom score was higher with momelotinib than with danazol.
The proportion of patients with a 50% or greater reduction in total symptom score was higher with momelotinib than with danazol.
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Researchers uncovered higher-than-anticipated rates of thrombosis, hemorrhage, and disease transformation in a real-world cohort of young MPN patients.
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.
A mobile app that tracks exercise is feasible for older patients receiving chemotherapy for myeloid neoplasms.
Established general guidelines for cancer-related fatigue may help patients with myeloproliferative neoplasms.
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
A single-center study sought to determine the effects of SARS-CoV-2 vaccination in patients with myeloproliferative neoplasms.